



Thomas F. Baumert, MD is Professor of Medicine, head of the Inserm Research Institute for Viral and Liver Diseases (Inserm U1110), director of the Laboratory of Excellence HEPSYS at the University of Strasbourg and Chair of Hepatology at the Center for Digestive Disease and Hepatology at the Strasbourg University Hospitals.

He received his MD from the University of Heidelberg, Germany. Following his doctoral thesis at the German Cancer Research Center (DKFZ) in Heidelberg and his internship in Internal Medicine at the Ludwig Maximilians University in Munich, he was a postdoctoral fellow at Harvard Medical School, Massachusetts General Hospital, and the Liver Diseases Branch at the National Institutes of Health, Bethesda, USA. He subsequently joined the Department of Medicine at the University Hospital in Freiburg, Germany to become a board-certified internist and gastroenterologist, associate professor and to establish his laboratory focussing on the molecular pathogenesis of hepatitis B and C virus infection. He then relocated to the University of Strasbourg in France as full Professor of Medicine to create and head a new Inserm research unit on virus-host interactions and liver disease and establish a highly recognized program in translational virology and hepatology. He recently finished a sabbatical as a research scholar the BROAD Institute of MIT and Harvard, Cambridge, USA and the Massachusetts General Hospital, Harvard Medical School, Boston.

His laboratory focuses on the modelling and discovery of the cell circuits underlying virus-host interactions and disease. As a model he uses chronic hepatitis B and C virus (HBV, HCV) infection – the major cause of chronic liver disease and cancer worldwide. The understanding of the molecular mechanisms of virus-host interactions and disease biology has allowed his laboratory to uncover novel strategies for prevention and treatment of chronic viral hepatitis, liver disease and hepatocellular carcinoma. He has received several awards including the *Hans Popper Young Investigator Award*, the *Chair of Excellence and Laboratory of Excellence Awards* of the French National Research Agency and the *Infectious Disease Award* of the German Infectious Disease Society. He has been awarded the *Prix Galien France* and *Prix Galien International* for the discovery of host-targeting entry inhibitors for HCV infection. He recently received two *European Research Council* grants (ERC AdG and ERC PoC) for the discovery and development of novel approaches to prevent and treat chronic liver disease. He has published more than 250 scientific articles including *N. Engl. J. Med.*, *Lancet*, *Cell*, *Nature Medicine*, *Nature Biotechnology*, *Cell Host & Microbe*, *PNAS*, *J. Clin. Invest.* and *J. Exp. Med.* as a senior author. He is an inventor on 15 patents and patent applications. In his translational work he focuses on novel approaches for HBV cure, development of an HCV vaccine and prevention of liver cancer.

Research in his laboratory is supported by the European Union (ERC, H2020), the US National Institutes of Health (NIAID and NCI), the *Agence Nationale de Recherches sur le Sida, hépatites virales B et C* (ANRS), the *Agence Nationale de Recherche* (ANR), the University of Strasbourg Foundation, as well as industry. He has finished a five-year-term as an Associate Editor for the *Journal of Hepatology* and serves as a member of the editorial board of several journals in the field of Hepatology and Virology. He actively participates in structuring national and international research programs in Translational Medicine by serving as on various review and organizing committees.